STOCK TITAN

BroadOak reports 16% Harvard Bioscience (HBIO) stake tied to loans and warrants

Filing Impact
(Moderate)
Filing Sentiment
(Neutral)
Form Type
SCHEDULE 13D

Rhea-AI Filing Summary

BroadOak Income Fund, BroadOak Fund VI, BroadOak Capital Partners, and William Snider report significant ownership in Harvard Bioscience common stock. Mr. Snider is deemed to beneficially own 846,000 shares, or 15.97% of the company, based on 4,471,989 shares outstanding as of March 5, 2026, including shares underlying warrants and a convertible loan.

The position arises from a senior secured Loan and Security Agreement under which Harvard Bioscience obtained three term loans of $10.0 million, $22.5 million, and $7.5 million. The Term C Loan is convertible into common stock at $10.00 per share and can automatically convert if the share price exceeds $15.00 for thirty consecutive trading days. Lenders also received seven‑year warrants for 200,000 shares at a $5.00 exercise price and an effective resale registration statement.

The loans bear interest at not less than 12.80% per year initially, include prepayment premiums and a 10.00% exit fee on repaid amounts, and are secured by substantially all assets of Harvard Bioscience and its guarantor subsidiaries. Proceeds are used to refinance the prior credit facility, pay transaction costs, and support working capital and general corporate purposes. BroadOak, through the administrative agent, obtained the right to nominate one director; Mr. Snider has been appointed to the board and its compensation committee and may receive director compensation and equity awards. He also purchased 21,000 shares in open‑market transactions in March 2026 with personal funds.

Positive

  • None.

Negative

  • None.

Insights

High-cost secured financing with sizable potential equity overhang and governance influence.

Harvard Bioscience has taken on three senior secured term loans totaling $10.0 million, $22.5 million, and $7.5 million. The interest rate is at least 12.80% initially, with step-downs and a prime-based floor, plus prepayment premiums and a 10.00% exit fee on repaid amounts. This is expensive capital but delivers immediate refinancing and liquidity, secured against substantially all assets.

The $7.5 million Term C Loan is convertible at $10.00 per share and may automatically convert if the stock trades above $15.00 for thirty consecutive days, on top of seven-year warrants for 200,000 shares at $5.00. Together with existing shares, BroadOak-related entities report up to 15.97% beneficial ownership, indicating meaningful potential dilution from full conversion and warrant exercise.

Governance influence is also notable. The loan package grants the administrative agent a board nomination right, and William Snider has joined the board and compensation committee. The agreement contemplates a Product, Operations and Scientific Advisory Board with members appointed by the company and the administrative agent by March 31, 2026. Future filings may show how often BroadOak adjusts its position through the registered resale, open‑market trades, or additional financings.






If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of §§ 240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the following box.

The information required on the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).




schemaVersion:


SCHEDULE 13D






SCHEDULE 13D






SCHEDULE 13D






SCHEDULE 13D




Comment for Type of Reporting Person:
Note to Rows 7, 9, and 11: Consists of 21,000 shares of Harvard Bioscience, Inc. (the "Issuer") common stock, par value $0.01 per share ("Common Stock") held by William Snider. Note to Rows 8, 10 and 11: Consists of (i) 60,000 shares of Common Stock issuable upon the exercise of warrants held by BroadOak Income Fund, L.P. ("BroadOak Income Fund"); (ii) 15,000 shares of Common Stock issuable upon the exercise of the warrants held by BroadOak Fund VI, L.P. ("BroadOak Fund VI"); and (iii) 750,000 shares of Common Stock issuable upon the conversion of the convertible loan held by BroadOak Income Fund. BroadOak Capital Partners, LLC ("BroadOak Capital Partners") is the parent of BroadOak Income Fund and BroadOak Fund VI (collectively, the "BroadOak Funds"), and as such may be deemed to share beneficial ownership of the shares of Common Stock underlying the warrants and convertible loan held by the BroadOak Funds. William Snider has sole voting and dispositive power over the shares of common stock underlying the warrants and convertible loan held by the BroadOak Funds, and as such may be deemed to share beneficial ownership of such shares. The number of shares held by the Reporting Persons as disclosed in this filing reflects the 10:1 reverse stock split of the Common Stock effected by the Issuer on March 13, 2026 (the "Stock Split"). Note to Row 13: Based on (i) 4,471,989 shares of Common Stock outstanding as of March 5, 2026, as reported in the Issuer's Form 10-K filed with the U.S. Securities and Exchange Commission (the "SEC") on March 13, 2026, as adjusted to reflect the Stock Split, and (ii) assumes the issuance of shares of Common Stock underlying the warrants and convertible loans held by the BroadOak Funds in the following amounts, as adjusted to reflect the Stock Split: with respect to (A) BroadOak Income Fund, 810,000 shares; (B) BroadOak Fund VI, 15,000 shares; and (C) BroadOak Capital Partners and Mr. Snider, 825,000 shares.


SCHEDULE 13D


BroadOak Income Fund, L.P.
Signature:/s/ William Snider
Name/Title:William Snider, Manager
Date:03/23/2026
BroadOak Fund VI, L.P.
Signature:/s/ William Snider
Name/Title:William Snider, Manager
Date:03/23/2026
BroadOak Capital Partners, LLC
Signature:/s/ William Snider
Name/Title:William Snider, Partner
Date:03/23/2026
William Snider
Signature:/s/ William Snider
Name/Title:William Snider
Date:03/23/2026

FAQ

What stake in Harvard Bioscience (HBIO) does BroadOak report in this Schedule 13D?

BroadOak-related entities report beneficial ownership of up to 15.97% of Harvard Bioscience common stock for William Snider, or 846,000 shares. This figure includes shares underlying warrants and a convertible loan, based on 4,471,989 shares outstanding as of March 5, 2026.

What are the key terms of Harvard Bioscience’s new loans from BroadOak?

Harvard Bioscience entered term loans of $10.0 million, $22.5 million, and $7.5 million. These senior secured loans mature on December 17, 2029, bear interest of at least 12.80% initially, include prepayment premiums, a 10.00% exit fee, and are secured by substantially all assets.

How is the Term C Loan to Harvard Bioscience convertible into HBIO stock?

The $7.5 million Term C Loan is a senior secured convertible loan maturing on December 17, 2029. It is convertible, with accrued interest, into common stock at $10.00 per share and may automatically convert if the share price exceeds $15.00 for thirty consecutive trading days.

What warrant rights did BroadOak receive from Harvard Bioscience (HBIO)?

Under the Loan Agreement, lenders received warrants to purchase 200,000 shares of Harvard Bioscience common stock at an exercise price of $5.00 per share. These warrants have a seven-year term, and the company has an effective registration statement covering resale of warrant and conversion shares.

What governance rights did BroadOak gain at Harvard Bioscience through this transaction?

The Administrative Agent under the Loan Agreement obtained the right to nominate one Harvard Bioscience director. The board appointed William Snider on December 17, 2025 to the board and compensation committee. The agreement also contemplates a new advisory board with two members appointed by the Administrative Agent.

How might BroadOak change its investment in Harvard Bioscience (HBIO) going forward?

The reporting persons state they may increase or decrease their position over time. They can transact through sales under an effective registration statement, open‑market or private purchases or sales, and other methods, subject to the Loan Agreement, company policies, and applicable securities laws.
Harvard Biosci

NASDAQ:HBIO

View HBIO Stock Overview

HBIO Rankings

HBIO Latest News

HBIO Latest SEC Filings

HBIO Stock Data

23.88M
40.80M
Medical Instruments & Supplies
Laboratory Analytical Instruments
Link
United States
HOLLISTON